Fluoxetine

Prozac, Sarafem, Symbyax, RECONCILE

Antidepressant • SSRI

Premium

QT RiskBleedingSerotoninergic

Half-life

1-3 days (norfluoxetine 4-16 days)

Protein Binding

94.5%

Metabolized By

CYP2D6, CYP2C9

External

Drugs.com

Boxed warning

Suicidality risk in children, adolescents, and young adults

Clinical alerts

Boxed warning

1 boxed warning

Bleeding risk

Additive with other antithrombotics and NSAIDs

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Serotonergic

Serotonin syndrome risk when combined with other serotonergic drugs

Mechanism of action

Selectively inhibits serotonin reuptake; active metabolite norfluoxetine

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Older Adults
·Anxiety
·Depression
·Major Surgical Resection of a Thoracic Malignancy
·Major Surgical Resection of an Abdominal Malignancy

Interactions

2 curated · 2 major or contraindicated · select a row for management

Interacting drug	Severity	Effect
tamoxifen	major	Reduced tamoxifen efficacy; increased breast cancer recurrence risk
tramadol	major	Serotonin syndrome and reduced pain control with paradoxically increased seizure risk.

Common adverse effects

Nausea
Insomnia
Anxiety
Sexual dysfunction
Weight loss

Food, alcohol & herbal

Alcohol · major

Increased CNS depression. Avoid alcohol.

Herbal

St. John's Wort (major) — Serotonin syndrome risk — CONTRAINDICATED

Pharmacokinetics

Half-life: 1-3 days (norfluoxetine 4-16 days)
Protein binding: 94.5%
Metabolised by: CYP2D6, CYP2C9
Inhibits: CYP2D6, CYP2C19, CYP3A4

Pregnancy & lactation

Not recorded for Fluoxetine. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, curated interaction pairs.

Not a substitute for clinical judgement

Fluoxetine

Prozac, Sarafem, Symbyax, RECONCILE

Antidepressant • SSRI

Premium

QT RiskBleedingSerotoninergic

Half-life

1-3 days (norfluoxetine 4-16 days)

Protein Binding

94.5%

Metabolized By

CYP2D6, CYP2C9

External

Drugs.com

Boxed warning

Suicidality risk in children, adolescents, and young adults

Clinical alerts

Boxed warning

1 boxed warning

Bleeding risk

Additive with other antithrombotics and NSAIDs

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Serotonergic

Serotonin syndrome risk when combined with other serotonergic drugs

Mechanism of action

Selectively inhibits serotonin reuptake; active metabolite norfluoxetine

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Older Adults
·Anxiety
·Depression
·Major Surgical Resection of a Thoracic Malignancy
·Major Surgical Resection of an Abdominal Malignancy

Interactions

2 curated · 2 major or contraindicated · select a row for management

Interacting drug	Severity	Effect
tamoxifen	major	Reduced tamoxifen efficacy; increased breast cancer recurrence risk
tramadol	major	Serotonin syndrome and reduced pain control with paradoxically increased seizure risk.

Common adverse effects

Nausea
Insomnia
Anxiety
Sexual dysfunction
Weight loss

Food, alcohol & herbal

Alcohol · major

Increased CNS depression. Avoid alcohol.

Herbal

St. John's Wort (major) — Serotonin syndrome risk — CONTRAINDICATED

Pharmacokinetics

Half-life: 1-3 days (norfluoxetine 4-16 days)
Protein binding: 94.5%
Metabolised by: CYP2D6, CYP2C9
Inhibits: CYP2D6, CYP2C19, CYP3A4

Pregnancy & lactation

Not recorded for Fluoxetine. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, curated interaction pairs.

Not a substitute for clinical judgement

Fluoxetine Drug Profile | PharmaGraphX